NCT07251088 Dyadic, App-supported Collaborative Care Intervention Trial for Family Caregivers of People Living With Dementia
| NCT ID | NCT07251088 |
| Status | Recruiting |
| Phase | — |
| Sponsor | German Center for Neurodegenerative Diseases (DZNE) |
| Condition | Dementia |
| Study Type | INTERVENTIONAL |
| Enrollment | 554 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 554 participants in total. It began in 2026-01-01 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In Germany, approximately 1.8 million individuals are living with dementia, representing a considerable share of those requiring long-term care. Many people with dementia (PlwD) express the desire to remain in their home environment for as long as possible. However, the progressive cognitive and physical decline associated with the disease renders caregiving increasingly time-intensive and places a substantial burden on family members. In the absence of sufficient support structures, maintaining home-based care becomes difficult, creating additional strain on the health care system. The study aims to address these challenges through an innovative intervention. Its primary objectives are: (1) to evaluate whether a dyadic care management model, delivered by specialized nurses with expertise in dementia care and supported by a mobile health application that provides direct access to caregiving experts and memory clinics, can help stabilize the home care situation; (2) to determine whether this approach reduces caregiver burden; and (3) to assess its effectiveness in alleviating neuropsychiatric symptoms in PlwD, compared to usual care.
Eligibility Criteria
Inclusion Criteria: * formal dementia diagnosis * living in their own home for the person with dementia * access to a smartphone and internet for the informal caregiver * informed consent of the participant Exclusion Criteria: * not able to provide written consent * if a legal representative is present, they may give their consent
Contact & Investigator
Bernhard Michalowsky, PD Dr. Dr.
PRINCIPAL INVESTIGATOR
German Center for Neurodegenerative Diseases (DZNE)
Frequently Asked Questions
Who can join the NCT07251088 clinical trial?
This trial is open to participants of all sexes, studying Dementia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07251088 currently recruiting?
Yes, NCT07251088 is actively recruiting participants. Contact the research team at bernhard.michalowsky@dzne.de for enrollment information.
Where is the NCT07251088 trial being conducted?
This trial is being conducted at Karlsruhe, Germany, Konstanz, Germany, Reutlingen, Germany, Darmstadt, Germany and 8 additional locations.
Who is sponsoring the NCT07251088 clinical trial?
NCT07251088 is sponsored by German Center for Neurodegenerative Diseases (DZNE). The principal investigator is Bernhard Michalowsky, PD Dr. Dr. at German Center for Neurodegenerative Diseases (DZNE). The trial plans to enroll 554 participants.